Menu Search
Equities

Telo Genomics Corp

3D0A:DEU

Telo Genomics Corp

Actions
  • Price (EUR)0.08
  • Today's Change-0.003 / -3.61%
  • Shares traded0.00
  • 1 Year change-36.00%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Telo Genomics Corp. is a biotech company pioneering the telomere platform in the industry with applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. The Company's lead application, TELO-MM is being developed to provide actionable information to medical professionals in the treatment of multiple myeloma, a form of blood cancer. Its clinical studies and product development design includes TeloView SMM, TeloView Test to Predict Patient Resistance to Treatment, development in collaboration with the Mayo Clinic and TeloView Test to monitor minimal residual disease in MM patients. The Company, by combining quantitative analysis of three-dimensional telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, is developing products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-2.71m
  • Incorporated2011
  • Employees8.00
  • Location
    Telo Genomics CorpMars Centre, 101 College St Suite 200TORONTO M5G 1L7CanadaCAN
  • Phone+1 (416) 673-8487
  • Fax+1 (204) 582-0922
  • Websitehttps://www.telodx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.